Boston Scientific Corporation (BSX)

35.44
0.45 1.25
NYSE
Prev Close 35.89
Open 35.00
Day Low/High 34.78 / 36.14
52 Wk Low/High 26.27 / 40.81
Volume 19.82M
Exchange NYSE
Shares Outstanding 1390.50B
Market Cap 48.57B
Div & Yield N.A. (N.A)
Boston Scientific Announces Results For First Quarter 2019

Boston Scientific Announces Results For First Quarter 2019

MARLBOROUGH, Mass., April 24, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated sales of $2.

Boston Scientific Receives FDA Approval For LOTUS Edge™ Aortic Valve System

Boston Scientific Receives FDA Approval For LOTUS Edge™ Aortic Valve System

Transcatheter Aortic Valve Replacement Technology for Patients with Severe Aortic Stenosis Designed to Minimize Paravalvular Leakage, Offer Controlled Delivery and Repositionability Post Deployment

Lifshitz & Miller LLP Announces Investigation Of Advanced Disposal Services, Inc., Boston Scientific Corporation, Cavco Industries, Inc., Evoqua Water Technologies Corp., HomeFed Corporation, KeyW Holding Corporation, Level Brands, Inc., And Nightstar Therapeutics Plc.

Lifshitz & Miller LLP Announces Investigation Of Advanced Disposal Services, Inc., Boston Scientific Corporation, Cavco Industries, Inc., Evoqua Water Technologies Corp., HomeFed Corporation, KeyW Holding Corporation, Level Brands, Inc., And Nightstar Therapeutics Plc.

NEW YORK, April 23, 2019 /PRNewswire/ -- Advanced Disposal Services, Inc. (ADSW) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the proposed sale of ADSW to Waste Management, Inc.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Boston Scientific Corporation - BSX

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Boston Scientific Corporation - BSX

NEW YORK, April 19, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX).

Boston Scientific Announces Conference Call Discussing First Quarter 2019 Financial Results

Boston Scientific Announces Conference Call Discussing First Quarter 2019 Financial Results

MARLBOROUGH, Mass., March 27, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2019 on Wednesday, April 24, 2019 at...

Late-breaking Clinical Trial Highlights Positive Safety And Efficacy Data For The LUMINIZE™ RF Balloon Catheter

Late-breaking Clinical Trial Highlights Positive Safety And Efficacy Data For The LUMINIZE™ RF Balloon Catheter

New data showcasing performance of recently acquired RF balloon-based, single-shot ablation technology

Boston Scientific Receives CE Mark For Next Generation WATCHMAN FLX™ Left Atrial Appendage Closure Device

Boston Scientific Receives CE Mark For Next Generation WATCHMAN FLX™ Left Atrial Appendage Closure Device

Company begins limited market release in Europe

Boston Scientific Announces Scheduled Data At EHRA 2019 Congress

Boston Scientific Announces Scheduled Data At EHRA 2019 Congress

MARLBOROUGH, Mass., March 11, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced key data that will be featured at EHRA 2019, the annual congress of the European Heart Rhythm Association (EHRA) in Lisbon, Portugal, on March...

Boston Scientific Prices $4.3 Billion Of Senior Notes

Boston Scientific Prices $4.3 Billion Of Senior Notes

MARLBOROUGH, Mass., Feb.

Boston Scientific Announces Results For Fourth Quarter And Full Year 2018

Boston Scientific Announces Results For Fourth Quarter And Full Year 2018

MARLBOROUGH, Mass., Feb.

Boston Scientific Launches Vercise™ Primary Cell And Vercise Gevia™ Deep Brain Stimulation Systems With Directional Leads

Boston Scientific Launches Vercise™ Primary Cell And Vercise Gevia™ Deep Brain Stimulation Systems With Directional Leads

Advanced systems offer customizable therapy addressing progression of Parkinson's disease

VICI VENOUS STENT® System Demonstrates Positive Clinical Outcomes In Patients With Deep Venous Blockages

VICI VENOUS STENT® System Demonstrates Positive Clinical Outcomes In Patients With Deep Venous Blockages

Results from the VIRTUS Study Show Venous Stent Met Its Primary Effectiveness and Safety Endpoints in Re-establishing Blood Flow at Twelve Months

Edwards Lifesciences' Stock Jumps on Patent Dispute Settlement

Edwards Lifesciences' Stock Jumps on Patent Dispute Settlement

Shares jump nearly 8% following agreement to pay rival Boston Scientific Corp. 4180 million to settle long-standing patent disputes.

Boston Scientific, Edwards Lifesciences Agree To Global Litigation Settlement

Boston Scientific, Edwards Lifesciences Agree To Global Litigation Settlement

All Patent Litigation Between the Companies to be Dismissed

Boston Scientific Exercises Option To Acquire Millipede, Inc.

Boston Scientific Exercises Option To Acquire Millipede, Inc.

Acquisition will expand structural heart portfolio to include transcatheter mitral annuloplasty repair system

Boston Scientific Prevails In U.S. Edwards Lifesciences Litigation

Boston Scientific Prevails In U.S. Edwards Lifesciences Litigation

Delaware Court Rules Edwards Lifesciences Infringes Boston Scientific Patent

Shire, Abbott Labs May Pace Healthcare Stocks in 2019

Shire, Abbott Labs May Pace Healthcare Stocks in 2019

Healthcare has been the best performing sector of the market this year. Here are three buy-rated stocks to track now.

When Will the Pain End?: Cramer's 'Mad Money' Recap (Tuesday 11/27/18)

When Will the Pain End?: Cramer's 'Mad Money' Recap (Tuesday 11/27/18)

Jim Cramer says most - but not all - stocks are in a bear market. He talks about what's happening with Clorox, Coca-Cola, Verizon, Apple and more.

Analog Devices, MongoDB, Welltower: 'Mad Money' Lightning Round

Analog Devices, MongoDB, Welltower: 'Mad Money' Lightning Round

Jim Cramer takes a look at Analog Devices, MongoDB, Welltower, Ventas, Iridium Communications, Huntington Bancshares, Citigroup, Randgold Resources and more.

Boston Scientific to Buy Britain's BTG for $4.2 Billion

Boston Scientific to Buy Britain's BTG for $4.2 Billion

Boston Scientific offered $10.77 for each BTG share, valuing the company at $4.2 billion.

TheStreet Quant Rating: B (Buy)